SCHEMBL4264396

SCHEMBL4264396

O=c1oc(Nc2ccccc2Oc2ccccc2)nc2sc(Cl)cc12

nearest known ligand 0.46

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
C1R P00736 18/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4268147 0.88 C1R (0.47) C1RNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4259213 0.87 C1R (0.46) C1RNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4258175 0.87 ELANE (0.46) C1RNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4264585 0.85 C1R (0.47) C1RNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4260532 0.84 C1R (0.43) C1RNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4266487 0.84 C1R (0.43) C1RNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4260423 0.84 C1R (0.51) C1RNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4262993 0.84 C1R (0.43) C1RNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4263346 0.83 C1R (0.43) C1RNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4262925 0.81 ELANE (0.49) C1RNPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1446125-B1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LTD (GB) 2009-04-29 EP claimed
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LIMITED (GB) 2009-01-29 US claimed
US-7407954-B2 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity ALIZYME THERAPEUTICS LIMITED (GB) 2008-08-05 US claimed
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity NORGINE B.V. (NL) 2005-04-07 US claimed
EP-1446125-B1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LTD (GB) 2009-04-29 EP disclosed
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LIMITED (GB) 2009-01-29 US disclosed
US-7407954-B2 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity ALIZYME THERAPEUTICS LIMITED (GB) 2008-08-05 US disclosed
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity NORGINE B.V. (NL) 2005-04-07 US disclosed
EP-1446125-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY Alizyme Therapeutics Limited (GB) 2004-08-18 EP disclosed
WO-2003020282-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LIMITED (GB) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity LPL, LIPE, LIPC C1R 3110/4885NPC1 725/4885RAB9A 4095/4885
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY LPL, LIPE, LIPC C1R 3110/4885NPC1 725/4885RAB9A 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.